{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T15:13:58Z","timestamp":1742397238873,"version":"3.37.3"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,28]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We read the excellent viewpoint by Slavin et al. (J Antimicrob Chemother 2022; 77: 16\u201323) that draws upon the experience of an advisory board of notable experts to comprehensively address many of the clinical factors that drive the need for changes in antifungal therapy for invasive aspergillosis (IA). As noted by the authors, there remains a paucity of quality data to support many of the decisions faced by clinicians managing patients with IA. However, we would like to highlight several other important issues, not fully addressed in that viewpoint, that play an important role in deciding when to change antifungal therapy for IA.<\/jats:p>","DOI":"10.1093\/jac\/dkac301","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T05:18:58Z","timestamp":1662355138000},"page":"2897-2900","source":"Crossref","is-referenced-by-count":3,"title":["Quandaries of deciding when to change first-line therapy in invasive pulmonary aspergillosis"],"prefix":"10.1093","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0793-8491","authenticated-orcid":false,"given":"Arnaldo L","family":"Colombo","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Special Mycology Laboratory-LEMI, Federal University of S\u00e3o Paulo , S\u00e3o Paulo , Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3766-026X","authenticated-orcid":false,"suffix":"Jr","given":"Jo\u00e3o N","family":"De Almeida","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Special Mycology Laboratory-LEMI, Federal University of S\u00e3o Paulo , S\u00e3o Paulo , Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2002-4339","authenticated-orcid":false,"given":"Russell E","family":"Lewis","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, University of Bologna , Bologna , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios P","family":"Kontoyiannis","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Infection Control and Employee Health, MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,9,5]]},"reference":[{"key":"2022102819180363300_dkac301-B1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/jac\/dkab317","article-title":"When to change treatment of acute invasive aspergillosis: an expert viewpoint","volume":"77","author":"Slavin","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2022102819180363300_dkac301-B2","first-page":"1621","article-title":"Breakthrough invasive mold infections in the hematology patient: current concepts and future directions","volume":"67","author":"Lionakis","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2022102819180363300_dkac301-B3","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/cid\/ciy859","article-title":"Voriconazole resistance and mortality in invasive aspergillosis: a multicenter retrospective cohort study","volume":"68","author":"Lestrade","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2022102819180363300_dkac301-B4","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1093\/mmy\/myy081","article-title":"Why are so many cases of invasive aspergillosis missed?","volume":"57","author":"Danion","year":"2019","journal-title":"Med Mycol"},{"key":"2022102819180363300_dkac301-B5","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"2022102819180363300_dkac301-B6","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/jac\/dku410","article-title":"Concomitant occurrence of itraconazole-resistant and -susceptible strains of Aspergillus fumigatus in routine cultures","volume":"70","author":"Ahmad","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2022102819180363300_dkac301-B7","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/jac\/dkx423","article-title":"Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial","volume":"73","author":"Kontoyiannis","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2022102819180363300_dkac301-B8","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jinf.2012.05.001","article-title":"Concurrent lung infections in patients with hematological malignancies and invasive pulmonary aspergillosis: how firm is the Aspergillus diagnosis?","volume":"65","author":"Georgiadou","year":"2012","journal-title":"J Infect"},{"key":"2022102819180363300_dkac301-B9","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00793-21","article-title":"StenoSCORE: predicting Stenotrophomonas maltophilia bloodstream infections in the hematologic malignancy population","volume":"65","author":"Karaba","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2022102819180363300_dkac301-B10","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/cid\/ciab1070","article-title":"Investigational antifungal agents for invasive mycoses: a clinical perspective","volume":"75","author":"Lamoth","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2022102819180363300_dkac301-B11","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1200\/JCO.2003.01.144","article-title":"Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response","volume":"21","author":"Erasmus","year":"2003","journal-title":"J Clin Oncol"},{"key":"2022102819180363300_dkac301-B12","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jinf.2014.12.020","article-title":"Immune reconstitution inflammatory syndrome in neutropenic patients with invasive pulmonary aspergillosis","volume":"70","author":"Jung","year":"2015","journal-title":"J Infect"},{"key":"2022102819180363300_dkac301-B13","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/cid\/cix687","article-title":"Call for action: invasive fungal infections associated with ibrutinib and other small molecule kinase inhibitors targeting immune signaling pathways","volume":"66","author":"Chamilos","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2022102819180363300_dkac301-B14","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/QCO.0000000000000656","article-title":"Infections associated with the new \u2018nibs and mabs\u2019 and cellular therapies","volume":"33","author":"Maus","year":"2020","journal-title":"Curr Opin Infect Dis"},{"key":"2022102819180363300_dkac301-B15","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/myc.12960","article-title":"Defining breakthrough invasive fungal infection\u2013position paper of the Mycoses Study Group Education and Research Consortium and the European Confederation of Medical Mycology","volume":"62","author":"Cornely","year":"2019","journal-title":"Mycoses"},{"key":"2022102819180363300_dkac301-B16","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s15010-008-8129-5","article-title":"Occupation, lifestyle, diet, and invasive fungal infections","volume":"36","author":"Sipsas","year":"2008","journal-title":"Infection"},{"key":"2022102819180363300_dkac301-B17","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/cid\/ciz1195","article-title":"How long do we need to treat an invasive mold disease in hematology patients? Factors influencing duration of therapy and future questions","volume":"71","author":"Fern\u00e1ndez-Cruz","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2022102819180363300_dkac301-B18","doi-asserted-by":"crossref","first-page":"e573","DOI":"10.1016\/S2352-3026(22)00166-1","article-title":"[18F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial","volume":"9","author":"Douglas","year":"2022","journal-title":"Lancet Haematol"},{"key":"2022102819180363300_dkac301-B19","doi-asserted-by":"crossref","first-page":"e87784","DOI":"10.1371\/journal.pone.0087784","article-title":"Earlier diagnosis of invasive fusariosis with Aspergillus serum galactomannan testing","volume":"9","author":"Nucci","year":"2014","journal-title":"PLoS One"},{"key":"2022102819180363300_dkac301-B20","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jinf.2010.01.010","article-title":"Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998\u20132009","volume":"60","author":"Campo","year":"2010","journal-title":"J Infect"},{"key":"2022102819180363300_dkac301-B21","doi-asserted-by":"crossref","first-page":"iii25","DOI":"10.1093\/jac\/dkt390","article-title":"A multidisciplinary team approach to the management of patients with suspected or diagnosed invasive fungal disease","volume":"68","author":"Ben-Ami","year":"2013","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/11\/2897\/46680309\/dkac301.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/11\/2897\/46680309\/dkac301.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,26]],"date-time":"2023-11-26T04:31:38Z","timestamp":1700973098000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/77\/11\/2897\/6691804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,5]]},"references-count":21,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,9,5]]},"published-print":{"date-parts":[[2022,10,28]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkac301","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published-other":{"date-parts":[[2022,11,2]]},"published":{"date-parts":[[2022,9,5]]}}}